PT1163000E - Vacina contra antigénios de bactérias - Google Patents

Vacina contra antigénios de bactérias Download PDF

Info

Publication number
PT1163000E
PT1163000E PT00912626T PT00912626T PT1163000E PT 1163000 E PT1163000 E PT 1163000E PT 00912626 T PT00912626 T PT 00912626T PT 00912626 T PT00912626 T PT 00912626T PT 1163000 E PT1163000 E PT 1163000E
Authority
PT
Portugal
Prior art keywords
bacteriae
vaccine against
against antigens
antigens
vaccine
Prior art date
Application number
PT00912626T
Other languages
English (en)
Inventor
Carine Capiau
Marguerite Deschamps
Pierre Michel Desmons
Craig Antony Joseph Laferriere
Jan Poolman
Jean-Paul Prieels
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9906437.0A external-priority patent/GB9906437D0/en
Priority claimed from GBGB9909077.1A external-priority patent/GB9909077D0/en
Priority claimed from GBGB9909466.6A external-priority patent/GB9909466D0/en
Priority claimed from GBGB9916677.9A external-priority patent/GB9916677D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PT1163000E publication Critical patent/PT1163000E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/831—Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
PT00912626T 1999-03-19 2000-03-17 Vacina contra antigénios de bactérias PT1163000E (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9906437.0A GB9906437D0 (en) 1999-03-19 1999-03-19 Vaccine
GBGB9909077.1A GB9909077D0 (en) 1999-04-20 1999-04-20 Novel compositions
GBGB9909466.6A GB9909466D0 (en) 1999-04-23 1999-04-23 Vaccines
GBGB9916677.9A GB9916677D0 (en) 1999-07-15 1999-07-15 Vaccine

Publications (1)

Publication Number Publication Date
PT1163000E true PT1163000E (pt) 2008-03-20

Family

ID=27451884

Family Applications (2)

Application Number Title Priority Date Filing Date
PT00916983T PT1162999E (pt) 1999-03-19 2000-03-17 Vacina contra streptococcus pneumoniae
PT00912626T PT1163000E (pt) 1999-03-19 2000-03-17 Vacina contra antigénios de bactérias

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PT00916983T PT1162999E (pt) 1999-03-19 2000-03-17 Vacina contra streptococcus pneumoniae

Country Status (32)

Country Link
US (8) US20030147922A1 (pt)
EP (6) EP1776962A1 (pt)
JP (4) JP4846906B2 (pt)
KR (3) KR100642044B1 (pt)
CN (3) CN100339130C (pt)
AR (3) AR022963A1 (pt)
AT (3) ATE346608T1 (pt)
AU (3) AU750913B2 (pt)
BE (1) BE1025464I2 (pt)
BR (4) BR0009163A (pt)
CA (3) CA2366152A1 (pt)
CY (3) CY1107561T1 (pt)
CZ (3) CZ301445B6 (pt)
DE (4) DE60043930D1 (pt)
DK (2) DK1162999T3 (pt)
ES (3) ES2339737T3 (pt)
FR (1) FR10C0008I2 (pt)
HK (3) HK1043728B (pt)
HU (4) HU229968B1 (pt)
IL (5) IL145043A0 (pt)
LU (1) LU91652I2 (pt)
MX (1) MXPA01009452A (pt)
MY (2) MY125387A (pt)
NL (1) NL300415I1 (pt)
NO (4) NO330532B1 (pt)
NZ (3) NZ513840A (pt)
PL (3) PL355178A1 (pt)
PT (2) PT1162999E (pt)
SI (2) SI1162999T1 (pt)
TR (3) TR200102739T2 (pt)
TW (3) TWI286938B (pt)
WO (3) WO2000056360A2 (pt)

Families Citing this family (268)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030157129A1 (en) * 1995-06-23 2003-08-21 Smithkline Beecham Biologicals S.A. Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein
US7078042B2 (en) * 1995-09-15 2006-07-18 Uab Research Foundation Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
ES2283012T3 (es) 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Bacterioferritina de helicobacter pylori.
FR2763244B1 (fr) 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
US20010016200A1 (en) * 1998-04-23 2001-08-23 Briles David E. Pneumococcal surface protein C (PspC), epitopic regions and strain selection thereof, and uses therefor
BR9910643A (pt) 1998-05-22 2001-10-30 Loeb Health Res Inst At The Ot Processos e produtos para a indução de imunidadede mucosa
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
DE60043930D1 (de) 1999-03-19 2010-04-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
GB9925559D0 (en) * 1999-10-28 1999-12-29 Smithkline Beecham Biolog Novel method
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
NZ594877A (en) 2000-10-27 2012-07-27 Novartis Vaccines & Diagnostic Nucleic acids and proteins from streptococcus groups A & B
GB2370770B (en) * 2001-01-03 2005-06-01 Simon Connolly Uses of Streptococcus Vaccines
US7082569B2 (en) 2001-01-17 2006-07-25 Outlooksoft Corporation Systems and methods providing dynamic spreadsheet functionality
US8722062B2 (en) 2001-01-23 2014-05-13 Sanofi Pasteur, Inc. Multivalent meningococcal polysaccharide-protein conjugate vaccine
CA2438942A1 (en) 2001-02-23 2002-09-26 Glaxosmithkline Biologicals S.A. Influenza vaccine formulations for intradermal delivery
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
GB0109297D0 (en) * 2001-04-12 2001-05-30 Glaxosmithkline Biolog Sa Vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
US8481043B2 (en) 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
GB0118249D0 (en) 2001-07-26 2001-09-19 Chiron Spa Histidine vaccines
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
AR045702A1 (es) 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
ES2312649T3 (es) 2001-12-12 2009-03-01 Novartis Vaccines And Diagnostics S.R.L. Inmunizacion frente a chlamydia trachomatis.
GB0130215D0 (en) * 2001-12-18 2002-02-06 Glaxosmithkline Biolog Sa Vaccine
CA2476626A1 (en) 2002-02-20 2003-08-28 Chiron Corporation Microparticles with adsorbed polypeptide-containing molecules
MXPA04011248A (es) * 2002-05-14 2005-02-17 Chiron Srl Vacunas mucosales en combinacion para la meningitis bacteriana.
MXPA04011249A (es) * 2002-05-14 2005-06-06 Chiron Srl Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
JP4697706B2 (ja) 2002-10-11 2011-06-08 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル 高毒性髄膜炎菌系統に対する広範な防御のためのポリペプチド−ワクチン
CN102174533A (zh) * 2002-10-15 2011-09-07 英特塞尔股份公司 编码b族链球菌粘着因子的核酸、b族链球菌的粘着因子和它们的用途
EP1556477B1 (en) 2002-11-01 2017-08-09 GlaxoSmithKline Biologicals s.a. Drying process
PL229487B1 (pl) 2002-11-12 2018-07-31 Brigham & Womens Hospital Inc Kompozycja zawierająca polimer β-1,6-glukozaminy, kompozycja zawierająca przeciwciało, kompozycja farmaceutyczna, sposób wytwarzania wyodrębnionego polisacharydu, sposób identyfikacji obecności deacetylowanej poli-N-acetyloglukozaminy (dPNAG) i/ lub poli-N-acetyloglukozaminy (PNAG), wyodrębniony polisacharyd do zastosowania w leczeniu lub profilaktyce zakażenia, wyodrębniony polisacharyd do zastosowania do wytwarzania przeciwciał, w tym przeciwciał monoklonalnych, wyodrębniony polisacharyd do zastosowania w identyfikacji przeciwciała monoklonalnego
WO2004046177A2 (en) 2002-11-15 2004-06-03 Chiron Srl Unexpected surface proteins in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
JP2006512927A (ja) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
EP1585542B1 (en) 2002-12-27 2012-06-13 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
FR2850106B1 (fr) 2003-01-17 2005-02-25 Aventis Pasteur Conjugues obtenus par amination reductrice du polysaccharide capsulaire du pneumocoque de serotype 5
ES2383175T3 (es) * 2003-01-30 2012-06-18 Novartis Ag Vacunas inyectables contra múltiples serogrupos de meningococos
KR20060035581A (ko) * 2003-03-07 2006-04-26 와이어쓰 홀딩스 코포레이션 병원내 감염에 대한 면역화에 유용한다당류-스타필로코커스 표면 부착소 운반체 단백질 접합체
KR101052996B1 (ko) * 2003-03-13 2011-07-29 글락소스미스클라인 바이오로지칼즈 에스.에이. 박테리아 세포용해소에 대한 정제 공정
WO2004087153A2 (en) 2003-03-28 2004-10-14 Chiron Corporation Use of organic compounds for immunopotentiation
ES2596553T3 (es) 2003-06-02 2017-01-10 Glaxosmithkline Biologicals Sa Composiciones inmunogénicas a base de micropartículas que comprenden toxoide adsorbido y un antígeno que contiene un polisacárido
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
AU2004277758A1 (en) 2003-10-02 2005-04-14 Novartis Vaccines And Diagnostics S.R.L. Liquid vaccines for multiple meningococcal serogroups
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0500787D0 (en) 2005-01-14 2005-02-23 Chiron Srl Integration of meningococcal conjugate vaccination
GB0409745D0 (en) 2004-04-30 2004-06-09 Chiron Srl Compositions including unconjugated carrier proteins
WO2005105140A2 (en) 2004-04-30 2005-11-10 Chiron Srl Meningococcal conjugate vaccination
US7444197B2 (en) * 2004-05-06 2008-10-28 Smp Logic Systems Llc Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
GB0410866D0 (en) 2004-05-14 2004-06-16 Chiron Srl Haemophilius influenzae
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
EP1765313A2 (en) 2004-06-24 2007-03-28 Novartis Vaccines and Diagnostics, Inc. Compounds for immunopotentiation
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
WO2006078318A2 (en) 2004-07-29 2006-07-27 Novartis Vaccines And Diagnostics Inc. Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
PT2682126T (pt) 2005-01-27 2017-02-28 Children`S Hospital & Res Center At Oakland Vacinas de vesícula com base em agn1870 para proteção de amplo espetro contra doenças causadas por neisseria meningitidis
GB0502095D0 (en) 2005-02-01 2005-03-09 Chiron Srl Conjugation of streptococcal capsular saccharides
NZ580974A (en) 2005-02-18 2011-05-27 Novartis Vaccines & Diagnostic Immunogens from uropathogenic escherichia coli
HUE027400T2 (en) 2005-02-18 2016-10-28 Glaxosmithkline Biologicals Sa Proteins and nucleic acids from meningitis / sepsis with Escherichia coli
GB0505518D0 (en) 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US7709001B2 (en) * 2005-04-08 2010-05-04 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20060228380A1 (en) * 2005-04-08 2006-10-12 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
US7955605B2 (en) 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
US20070184072A1 (en) 2005-04-08 2007-08-09 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
CN101500601A (zh) 2005-04-18 2009-08-05 诺华疫苗和诊断公司 表达用于制备疫苗的乙型肝炎病毒表面抗原
MX2007016237A (es) 2005-06-27 2008-03-07 Glaxosmithkline Biolog Sa Composicion inmunogenica.
JP5135220B2 (ja) 2005-09-01 2013-02-06 ノバルティス ヴァクシンズ アンド ダイアグノスティクス ゲーエムベーハー アンド カンパニー カーゲー 血清群ｃ髄膜炎菌を含む複数ワクチン接種
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
US7527801B2 (en) 2005-11-22 2009-05-05 Novartis Vaccines And Diagnostics, Inc. Norovirus and Sapovirus antigens
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
GB0607088D0 (en) 2006-04-07 2006-05-17 Glaxosmithkline Biolog Sa Vaccine
LT2384765T (lt) 2005-12-22 2017-01-10 Glaxosmithkline Biologicals S.A. Streptococcus pneumoniae vakcina
EP1973933B1 (en) * 2006-01-17 2020-06-24 Forsgren, Arne A NOVEL SURFACE EXPOSED HAEMOPHILUS INFLUENZAE PROTEIN (PROTEIN E; pE)
CN101024079B (zh) * 2006-02-17 2012-02-01 福州昌晖生物工程有限公司 肺炎链球菌多糖-外膜蛋白结合疫苗及制备方法
KR20130135399A (ko) * 2006-03-17 2013-12-10 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 복합 다가 면역원성 콘쥬게이트의 제조 방법
AU2007229449A1 (en) 2006-03-22 2007-10-04 Novartis Ag Regimens for immunisation with meningococcal conjugates
US10828361B2 (en) 2006-03-22 2020-11-10 Glaxosmithkline Biologicals Sa Regimens for immunisation with meningococcal conjugates
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
ES2536426T3 (es) 2006-03-23 2015-05-25 Novartis Ag Compuestos de imidazoquinoxalina como inmunomoduladores
TWI494124B (zh) * 2006-03-30 2015-08-01 Glaxosmithkline Biolog Sa 免疫原組合物
MX337528B (es) * 2006-03-30 2016-03-09 Glaxosmithkline Biolog Sa Composición inmunogénica que comprende un sacárido capsular estafilocócico o-acetilado y una proteína estafilocócica.
TW200806315A (en) 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
US8808707B1 (en) 2006-05-08 2014-08-19 Wyeth Llc Pneumococcal dosing regimen
PT2054431E (pt) * 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
GB0612854D0 (en) 2006-06-28 2006-08-09 Novartis Ag Saccharide analysis
US20100166788A1 (en) 2006-08-16 2010-07-01 Novartis Vaccines And Diagnostics Immunogens from uropathogenic escherichia coli
ES2346929T3 (es) * 2006-10-10 2010-10-21 Wyeth Llc Procedimientos mejorados para la separacion de polisacaridos de streptococcus pneumoniae de tipo 3.
GB0700136D0 (en) 2007-01-04 2007-02-14 Glaxosmithkline Biolog Sa Process for manufacturing vaccines
GB0700562D0 (en) 2007-01-11 2007-02-21 Novartis Vaccines & Diagnostic Modified Saccharides
BRPI0813307C1 (pt) * 2007-06-26 2021-05-25 Glaxosmithkline Biologicals Sa composição imunogênica, vacina, e, processo para fabricar a vacina
GB0713880D0 (en) 2007-07-17 2007-08-29 Novartis Ag Conjugate purification
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
KR101621837B1 (ko) 2007-09-12 2016-05-17 노파르티스 아게 Ｇａｓ57 돌연변이 항원 및 ｇａｓ57 항체
EP2200642B1 (en) 2007-10-19 2012-04-18 Novartis AG Meningococcal vaccine formulations
JP2011503104A (ja) 2007-11-09 2011-01-27 カリフォルニア インスティテュート オブ テクノロジー 免疫調節化合物ならびに関連組成物および方法
JP2011506334A (ja) 2007-12-07 2011-03-03 ノバルティス アーゲー 免疫応答を誘導するための組成物
GB0818453D0 (en) 2008-10-08 2008-11-12 Novartis Ag Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
DK2235046T3 (da) 2007-12-21 2012-10-29 Novartis Ag Mutante former af streptolysin-O
US8226959B2 (en) * 2008-02-01 2012-07-24 Newcastle Innovation Pty Ltd Vaccine compositions
RU2475496C2 (ru) 2008-02-21 2013-02-20 Новартис Аг МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHBP
US9511131B2 (en) 2008-03-10 2016-12-06 Children's Hospital & Research Center Oakland Chimeric factor H binding proteins (fHBP) containing a heterologous B domain and methods of use
NZ591103A (en) 2008-07-21 2013-02-22 Brigham & Womens Hospital Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
ES2586308T3 (es) 2008-10-27 2016-10-13 Glaxosmithkline Biologicals Sa Procedimiento de purificación de un hidrato de carbono de Streptococcus del grupo A
JP5209800B2 (ja) 2008-12-09 2013-06-12 ファイザー バクシーンズ エルエルシー ＩｇＥＣＨ３ペプチドワクチン
GB0822633D0 (en) 2008-12-11 2009-01-21 Novartis Ag Formulation
GB0822634D0 (en) 2008-12-11 2009-01-21 Novartis Ag Meningitis vaccines
US8585505B2 (en) 2008-12-15 2013-11-19 Tetris Online, Inc. Inter-game interactive hybrid asynchronous computer game infrastructure
AU2009329193A1 (en) 2008-12-17 2011-07-14 Novartis Ag Meningococcal vaccines including hemoglobin receptor
WO2010078556A1 (en) 2009-01-05 2010-07-08 Epitogenesis Inc. Adjuvant compositions and methods of use
AU2010204139A1 (en) 2009-01-12 2011-08-11 Novartis Ag Cna_B domain antigens in vaccines against gram positive bacteria
PT2411048T (pt) 2009-03-24 2020-07-14 Glaxosmithkline Biologicals Sa Proteína de ligação ao fator h meningocócica com adjuvante
US20120064103A1 (en) 2009-03-24 2012-03-15 Novartis Ag Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
PL2510947T3 (pl) 2009-04-14 2016-09-30 Kompozycje do immunizacji przeciwko Staphylococcus aureus
WO2010132833A1 (en) 2009-05-14 2010-11-18 The Regents Of The University Of Michigan Streptococcus vaccine compositions and methods of using the same
BRPI1011753B8 (pt) 2009-06-22 2021-05-25 Wyeth Llc conjugados imunogênicos de polissacarídeo capsular de staphylococcus aureus de sorotipos 5 e 8, seu uso e composições que os compreendem
JP5395264B2 (ja) 2009-06-22 2014-01-22 ワイス・エルエルシー 黄色ブドウ球菌（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）抗原の免疫原性組成物
WO2011017101A2 (en) * 2009-07-27 2011-02-10 Fina Biosolutions, Llc Method for producing protein-carbohydrate vaccines reduced in free carbohydrate
MX2012001194A (es) 2009-07-30 2012-03-07 Pfizer Vaccines Llc Peptidos tau antigenicos y usos de los mismos.
ES2562259T3 (es) 2009-08-27 2016-03-03 Glaxosmithkline Biologicals Sa Polipéptidos híbridos que incluyen secuencias fHBP meningocócicas
EP2865752A1 (en) * 2009-09-03 2015-04-29 Pfizer Vaccines LLC PCSK9 vaccine
WO2011030218A1 (en) 2009-09-10 2011-03-17 Novartis Ag Combination vaccines against respiratory tract diseases
CN102917730A (zh) 2009-10-27 2013-02-06 诺华有限公司 修饰的脑膜炎球菌fHBP多肽
RU2579900C2 (ru) 2009-10-30 2016-04-10 Новартис Аг Очистка капсульных сахаридов staphylococcus aureus типа 5 и типа 8
GB0919690D0 (en) 2009-11-10 2009-12-23 Guy S And St Thomas S Nhs Foun compositions for immunising against staphylococcus aureus
WO2011084705A2 (en) 2009-12-17 2011-07-14 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
AU2010334428B2 (en) 2009-12-22 2015-05-21 Celldex Therapeutics, Inc. Vaccine compositions
GB201003333D0 (en) 2010-02-26 2010-04-14 Novartis Ag Immunogenic proteins and compositions
GB201003922D0 (en) 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Conjugation process
US9827300B2 (en) 2010-03-30 2017-11-28 Children's Hospital & Research Center Oakland Factor H binding proteins (FHBP) with altered properties and methods of use thereof
GB201005625D0 (en) 2010-04-01 2010-05-19 Novartis Ag Immunogenic proteins and compositions
HUE040658T2 (hu) 2010-04-07 2019-03-28 California Inst Of Techn Vivõanyag vegyület mukózus membránhoz juttatásához és kapcsolódó készítmények, eljárások és rendszerek
CA2800174A1 (en) * 2010-05-20 2011-11-24 June L. Round Antigen specific tregs and related compositions, methods and systems
CN102933229A (zh) 2010-06-04 2013-02-13 惠氏有限责任公司 疫苗制剂
WO2011154878A1 (en) 2010-06-07 2011-12-15 Pfizer Vaccines Llc Ige ch3 peptide vaccine
US8895017B2 (en) 2010-06-07 2014-11-25 Pfizer Inc. HER-2 peptides and vaccines
US10478483B2 (en) 2010-06-25 2019-11-19 Glaxosmithkline Biologicals Sa Combinations of meningococcal factor H binding proteins
GB201101665D0 (en) 2011-01-31 2011-03-16 Novartis Ag Immunogenic compositions
US20130315959A1 (en) 2010-12-24 2013-11-28 Novartis Ag Compounds
EP2667852B1 (en) 2011-01-27 2016-11-09 GlaxoSmithKline Biologicals SA Adjuvant nanoemulsions with crystallisation inhibitors
JP6191082B2 (ja) 2011-03-02 2017-09-06 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム より低用量の抗原および／またはアジュバントを有する混合ワクチン
GB201103836D0 (en) 2011-03-07 2011-04-20 Glaxosmithkline Biolog Sa Conjugation process
ES2785108T3 (es) 2011-03-24 2020-10-05 Glaxosmithkline Biologicals Sa Nanoemulsiones adyuvantes con fosfolípidos
EP2511295A1 (en) 2011-04-15 2012-10-17 Institut National De La Sante Et De La Recherche Medicale Compositions for preventing and/or treating an infection by an HIV-1 virus
EA030920B1 (ru) 2011-05-06 2018-10-31 Петр Геннадьевич АПАРИН Экзополисахарид бактерии shigella sonnei, способ его получения и включающие его вакцина и фармацевтическая композиция
CN107837394A (zh) 2011-06-24 2018-03-27 埃皮托吉尼西斯有限公司 作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物
JP6088507B2 (ja) 2011-07-08 2017-03-01 ノバルティス アーゲー チロシンライゲーションの方法
GB201114923D0 (en) 2011-08-30 2011-10-12 Novartis Ag Immunogenic proteins and compositions
EP2755683B1 (en) 2011-09-14 2019-04-03 GlaxoSmithKline Biologicals SA Methods for making saccharide-protein glycoconjugates
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
EP2776069A1 (en) 2011-11-07 2014-09-17 Novartis AG Carrier molecule comprising a spr0096 and a spr2021 antigen
EP2592137A1 (en) 2011-11-11 2013-05-15 Novartis AG Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
DE102011118371B4 (de) 2011-11-11 2014-02-13 Novartis Ag Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
GB2495341B (en) 2011-11-11 2013-09-18 Novartis Ag Fermentation methods and their products
DE102011122891B4 (de) 2011-11-11 2014-12-24 Novartis Ag Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
CN103974718A (zh) 2011-12-08 2014-08-06 诺华股份有限公司 基于艰难梭菌毒素的疫苗
GB201121301D0 (en) 2011-12-12 2012-01-25 Novartis Ag Method
JP2015505309A (ja) 2011-12-29 2015-02-19 ノバルティス アーゲー 髄膜炎菌ｈ因子結合タンパク質のアジュバントされた組み合わせ
CN104321335A (zh) 2012-02-24 2015-01-28 诺华股份有限公司 菌毛蛋白质和组合物
JP2015510872A (ja) 2012-03-07 2015-04-13 ノバルティス アーゲー Ｓｔｒｅｐｔｏｃｏｃｃｕｓｐｎｅｕｍｏｎｉａｅ抗原の増強された製剤
US20150125486A1 (en) 2012-03-08 2015-05-07 Novartis Ag Adjuvanted formulations of pediatric antigens
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
JP6401148B2 (ja) 2012-04-26 2018-10-03 ノバルティス アーゲー 抗原および抗原の組み合わせ
US10279026B2 (en) 2012-04-26 2019-05-07 Glaxosmithkline Biologicals Sa Antigens and antigen combinations
EP3563865A3 (en) 2012-05-04 2019-12-04 Pfizer Inc Prostate-associated antigens and vaccine-based immunotherapy regimens
KR20150021933A (ko) 2012-05-22 2015-03-03 노파르티스 아게 수막염구균 혈청군 x 포합체
KR102057217B1 (ko) 2012-06-20 2020-01-22 에스케이바이오사이언스 주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
WO2014037472A1 (en) 2012-09-06 2014-03-13 Novartis Ag Combination vaccines with serogroup b meningococcus and d/t/p
ES2690526T3 (es) 2012-10-03 2018-11-21 Glaxosmithkline Biologicals S.A. Composiciones inmunogénicas
EP2906239A1 (en) 2012-10-12 2015-08-19 GlaxoSmithKline Biologicals SA Non-cross-linked acellular pertussis antigens for use in combination vaccines
AU2013331781A1 (en) * 2012-10-17 2015-05-07 Glaxosmithkline Biologicals S.A. Immunogenic composition comprising 1 or more Streptococcus pneumoniae capsular saccharide conjugates and a protein component comprising Protein E and/or PilA from Haemophilus influenzae.
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
KR20140075201A (ko) * 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
KR20140075196A (ko) 2012-12-11 2014-06-19 에스케이케미칼주식회사 다가 폐렴구균 다당류-단백질 접합체 조성물
CA2899787A1 (en) 2013-02-01 2014-08-07 Glaxosmithkline Biologicals Sa Intradermal delivery of immunological compositions comprising toll-like receptor agonists
JP2016521284A (ja) 2013-05-10 2016-07-21 カリフォルニア インスティチュート オブ テクノロジー 大腸ガンのプロバイオティクスによる防止および処置
CN105263517B (zh) 2013-05-15 2021-03-26 阿尔伯达大学董事会 E1e2hcv疫苗及使用方法
CN103386126B (zh) * 2013-06-25 2015-06-17 北京科兴生物制品有限公司 一种含肠道病毒抗原的多价免疫原性组合物
KR101905278B1 (ko) 2013-09-08 2018-10-08 화이자 인코포레이티드 나이세리아 메닌지티디스 조성물 및 그의 방법
WO2015095868A1 (en) * 2013-12-20 2015-06-25 Wake Forest University Health Sciences Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
CN110787290A (zh) 2014-01-21 2020-02-14 辉瑞公司 包含缀合荚膜糖抗原的免疫原性组合物及其用途
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR102099741B1 (ko) 2014-01-21 2020-04-10 화이자 인코포레이티드 스트렙토코쿠스 뉴모니아에 피막 폴리사카라이드 및 그의 접합체
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
EA034954B1 (ru) 2014-02-28 2020-04-10 Глаксосмитклайн Байолоджикалс Са МОДИФИЦИРОВАННЫЕ МЕНИНГОКОККОВЫЕ ПОЛИПЕПТИДЫ fHbp
EP2921856B1 (en) * 2014-03-18 2016-09-14 Serum Institute Of India Private Limited A quantitative assay for 4-pyrrolidinopyridine (4-ppy) in polysaccharide-protein conjugate vaccines
CN104829711B (zh) * 2014-04-08 2018-04-03 北京天成新脉生物技术有限公司 脑膜炎球菌荚膜多糖单克隆抗体及其应用
JP6796057B2 (ja) 2014-07-23 2020-12-02 チルドレンズ ホスピタル アンド リサーチ センター アット オークランド Ｈ因子結合タンパク質変異体及びその使用方法
US9815886B2 (en) 2014-10-28 2017-11-14 Adma Biologics, Inc. Compositions and methods for the treatment of immunodeficiency
EP3034516A1 (en) 2014-12-19 2016-06-22 Novartis AG Purification of streptococcal capsular polysaccharide
SI3244917T1 (sl) 2015-01-15 2023-07-31 Pfizer Inc. Imunogenske kompozicije za uporabo v pnevmokoknih cepivih
CN104548090B (zh) * 2015-01-27 2016-11-30 中国科学院过程工程研究所 一种β-葡聚糖修饰的脑膜炎多糖结合疫苗及其制备方法
WO2016184963A1 (en) 2015-05-19 2016-11-24 Innavirvax Treatment of hiv-infected individuals
WO2016201342A1 (en) 2015-06-10 2016-12-15 California Institute Of Technology Sepsis treatment and related compositions methods and systems
EP3109255A1 (en) 2015-06-26 2016-12-28 Institut National De La Recherche Agronomique Immunogenic composition
AU2016289497A1 (en) 2015-07-07 2017-12-07 Affiris Ag Vaccines for the treatment and prevention of IgE mediated diseases
MX2018000867A (es) 2015-07-21 2018-05-15 Pfizer Composiciones inmunogenas que comprenden antigenos de sacarido capsular conjugados, kits que las comprenden y sus usos.
GB201518684D0 (en) 2015-10-21 2015-12-02 Glaxosmithkline Biolog Sa Vaccine
WO2017085586A1 (en) 2015-11-20 2017-05-26 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
MY199248A (en) 2015-12-04 2023-10-23 Dana Farber Cancer Inst Inc Vaccination with mica/b alpha 3 domain for the treatment of cancer
RU2020110148A (ru) 2016-01-19 2020-09-18 Пфайзер Инк. Противораковые вакцины
US11612664B2 (en) 2016-04-05 2023-03-28 Gsk Vaccines S.R.L. Immunogenic compositions
EP3474890A1 (en) * 2016-06-22 2019-05-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften E. V. Pneumococcal polysaccharide-protein conjugate composition
MX2019001341A (es) 2016-08-05 2019-07-04 Sanofi Pasteur Inc Composicion de conjugado de polisacarido neumococico multivalente-proteina.
SG11201900794PA (en) 2016-08-05 2019-02-27 Sanofi Pasteur Inc Multivalent pneumococcal polysaccharide-protein conjugate composition
AU2017321039B2 (en) 2016-09-02 2021-03-18 Glaxosmithkline Biologicals Sa Vaccines for Neisseria gonorrhoeae
US11478538B2 (en) 2016-10-07 2022-10-25 Enterome S.A. Immunogenic compounds for cancer therapy
KR20240007316A (ko) 2016-10-07 2024-01-16 엔터롬 에스.에이. 암 치료를 위한 면역원성 화합물
EP3551668A1 (en) 2016-12-06 2019-10-16 GlaxoSmithKline Biologicals S.A. Purification process for capsular polysaccharide
AU2018208844B2 (en) 2017-01-20 2021-02-25 Pfizer Inc. Immunogenic compositions for use in pneumococcal vaccines
SG11201906519RA (en) 2017-01-31 2019-08-27 Pfizer Neisseria meningitidis compositions and methods thereof
US10259865B2 (en) 2017-03-15 2019-04-16 Adma Biologics, Inc. Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infection
WO2018169303A1 (ko) * 2017-03-15 2018-09-20 주식회사 엘지화학 다가 폐렴구균 백신 조성물
BR112019020209A2 (pt) 2017-03-31 2020-06-02 Glaxosmithkline Intellectual Property Development Limited Composição imunogênica, uso de uma composição imunogênica, método de tratamento ou prevenção de uma recorrência de uma exacerbação aguda de doença pulmonar obstrutiva crônica, e, terapia de combinação.
WO2018178265A1 (en) 2017-03-31 2018-10-04 Glaxosmithkline Intellectual Property Development Limited Immunogenic composition, use and method of treatment
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
US10688170B2 (en) 2017-06-10 2020-06-23 Inventprise, Llc Multivalent conjugate vaccines with bivalent or multivalent conjugate polysaccharides that provide improved immunogenicity and avidity
US11723966B2 (en) 2017-08-14 2023-08-15 Glaxosmithkline Biologicals Sa Methods of boosting immune responses
MX2020005779A (es) 2017-12-06 2020-10-28 Merck Sharp & Dohme Composiciones que comprenden conjugados de polisacarido de streptococcus pneumoniae con proteina y metodos de uso de estos.
US11123417B2 (en) 2018-02-05 2021-09-21 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
KR20200121822A (ko) 2018-02-05 2020-10-26 사노피 파스퇴르 인코포레이티드 다가 폐렴구균성 다당류-단백질 접합체 조성물
US11633471B2 (en) 2018-03-06 2023-04-25 Unm Rainforest Innovations Compositions and methods for reducing serum triglycerides
US20210106652A1 (en) 2018-04-11 2021-04-15 Enterome S.A. Immunogenic Compounds For Treatment Of Fibrosis, Autoimmune Diseases And Inflammation
SI3773689T1 (sl) 2018-04-11 2023-02-28 Enterome S.A. Antigenski peptidi za preprečevanje in zdravljenje raka
WO2019203599A1 (ko) 2018-04-18 2019-10-24 에스케이바이오사이언스 주식회사 스트렙토코커스 뉴모니애 협막 다당류 및 그의 면역원성 접합체
WO2020016322A1 (en) 2018-07-19 2020-01-23 Glaxosmithkline Biologicals Sa Processes for preparing dried polysaccharides
JP2021533162A (ja) 2018-08-07 2021-12-02 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム プロセス及びワクチン
US11260119B2 (en) 2018-08-24 2022-03-01 Pfizer Inc. Escherichia coli compositions and methods thereof
WO2020120569A2 (en) 2018-12-12 2020-06-18 Glaxosmithkline Biologicals Sa Modified carrier proteins for o-linked glycosylation
EP3893926A1 (en) 2018-12-12 2021-10-20 Pfizer Inc. Immunogenic multiple hetero-antigen polysaccharide-protein conjugates and uses thereof
US20220296695A1 (en) 2018-12-19 2022-09-22 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
WO2020165711A1 (en) 2019-02-11 2020-08-20 Pfizer Inc. Neisseria meningitidiscompositions and methods thereof
JP7239509B6 (ja) 2019-02-22 2023-03-28 ファイザー・インク 細菌多糖類を精製するための方法
EP3952906A1 (en) 2019-04-10 2022-02-16 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
WO2020212461A1 (en) 2019-04-18 2020-10-22 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays
JP2022532142A (ja) 2019-05-10 2022-07-13 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム コンジュゲートの製造
BR112021026565A2 (pt) 2019-08-05 2022-05-03 Glaxosmithkline Biologicals Sa Composição imunogênica
CA3148928A1 (en) 2019-08-05 2021-02-11 Glaxosmithkline Biologicals Sa Process for preparing a composition comprising a protein d polypeptide
KR20220069992A (ko) 2019-09-27 2022-05-27 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
MX2022004598A (es) 2019-10-16 2022-09-23 Enterome S A Compuestos inmunogenicos para el tratamiento del cancer suprarrenal.
US20230000966A1 (en) 2019-11-01 2023-01-05 Pfizer Inc. Escherichia coli compositions and methods thereof
RS65262B1 (sr) 2019-11-15 2024-03-29 Enterome S A Antigenski peptidi za prevenciju i lečenje maligniteta b ćelija
EP4061412A1 (en) 2019-11-22 2022-09-28 GlaxoSmithKline Biologicals S.A. Dosage and administration of a bacterial saccharide glycoconjugate vaccine
US20220409539A1 (en) * 2019-12-30 2022-12-29 Fraunhofer Usa Inc. Particles for multi-dose delivery
AU2021224078B2 (en) 2020-02-21 2024-01-18 Pfizer Inc. Purification of saccharides
BR112022014555A2 (pt) 2020-02-23 2022-09-20 Pfizer Composições de escherichia coli e métodos das mesmas.
CN111588847B (zh) * 2020-05-18 2023-05-26 广州中医药大学(广州中医药研究院) 一种含有单磷酸化的脂质a与糖抗原的缀合物及其制备方法和应用
US20230250142A1 (en) 2020-06-12 2023-08-10 Glaxosmithkline Biologicals Sa Dock tag system
IL302362A (en) 2020-10-27 2023-06-01 Pfizer ESCHERICHIA COLI preparations and their methods
IL302413A (en) 2020-11-04 2023-06-01 Pfizer Immunogenic preparations for use in pneumococcal vaccines
JP2023549736A (ja) 2020-11-10 2023-11-29 ファイザー・インク コンジュゲートさせた莢膜糖抗原を含む免疫原性組成物およびその使用
US20220202923A1 (en) 2020-12-23 2022-06-30 Pfizer Inc. E. coli fimh mutants and uses thereof
KR20230147075A (ko) 2021-02-19 2023-10-20 사노피 파스퇴르 인크 수막구균 b 재조합 백신
EP4294433A1 (en) 2021-02-22 2023-12-27 GlaxoSmithKline Biologicals SA Immunogenic composition, use and methods
EP4070814A1 (en) 2021-04-07 2022-10-12 Lama France Sars-cov-2 polypeptides and uses thereof
WO2022249107A2 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3221074A1 (en) 2021-05-28 2022-12-01 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2023092090A1 (en) 2021-11-18 2023-05-25 Matrivax, Inc. Immunogenic fusion protein compositions and methods of use thereof
WO2023135515A1 (en) 2022-01-13 2023-07-20 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
KR20230116601A (ko) 2022-01-28 2023-08-04 이동민 머신 좌표계와 영상 좌표계의 정합 방법 및 장치
WO2023161817A1 (en) 2022-02-25 2023-08-31 Pfizer Inc. Methods for incorporating azido groups in bacterial capsular polysaccharides
WO2023187127A1 (en) 2022-03-31 2023-10-05 Enterome S.A. Antigenic peptides for prevention and treatment of cancer
WO2023218322A1 (en) 2022-05-11 2023-11-16 Pfizer Inc. Process for producing of vaccine formulations with preservatives

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4372945A (en) 1979-11-13 1983-02-08 Likhite Vilas V Antigen compounds
IL61904A (en) 1981-01-13 1985-07-31 Yeda Res & Dev Synthetic vaccine against influenza virus infections comprising a synthetic peptide and process for producing same
BE889979A (fr) 1981-08-14 1982-02-15 Smith Kline Rit Procede de preparation de polysaccharides bacteriens capsulaires antigeniques purifies, produits obtenus et leur utilisation
US5360897A (en) * 1981-08-31 1994-11-01 The University Of Rochester Immunogenic conjugates of streptococcus pneumonial capsular polymer and toxin or in toxiad
US4761283A (en) * 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) * 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US5173294A (en) 1986-11-18 1992-12-22 Research Foundation Of State University Of New York Dna probe for the identification of haemophilus influenzae
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
HUT58804A (en) * 1988-12-16 1992-03-30 James Cleland Paton Process for producing pneumolysine mutants and pneumococcus vaccines
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
NZ239643A (en) * 1990-09-17 1996-05-28 North American Vaccine Inc Vaccine containing bacterial polysaccharide protein conjugate and adjuvant (c-nd-che-a-co-b-r) with a long chain alkyl group.
CA2059692C (en) * 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US5552146A (en) 1991-08-15 1996-09-03 Board Of Regents, The University Of Texas System Methods and compositions relating to useful antigens of Moraxella catarrhalis
ATE156710T1 (de) 1992-06-25 1997-08-15 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
ATE211654T1 (de) * 1992-09-16 2002-01-15 Univ Tennessee Res Corp Antigene des hybriden m-proteins und träger für gruppe a streptokokkenimpfstoff
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
ATE226831T1 (de) 1993-05-18 2002-11-15 Univ Ohio State Res Found Impfstoff gegen mittelohrentzündung
CA2171942C (en) 1993-09-22 2010-12-14 Andrew Lees Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
ATE509102T1 (de) 1994-07-15 2011-05-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US5565204A (en) * 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
US5681570A (en) * 1995-01-12 1997-10-28 Connaught Laboratories Limited Immunogenic conjugate molecules
EP0824360A1 (en) * 1995-04-17 1998-02-25 Henry M. Jackson Foundation For The Advancement Of Military Medicine Induction and enhancement of the immune response to polysaccharides with bacterial lipoproteins
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6440425B1 (en) 1995-05-01 2002-08-27 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
HUP0600442A3 (en) 1995-06-07 2007-03-28 Biochem Vaccines Inc Streptococcal heat shock proteins members of the hsp70 family
US5736533A (en) * 1995-06-07 1998-04-07 Neose Technologies, Inc. Bacterial inhibition with an oligosaccharide compound
ES2164251T5 (es) 1995-06-07 2006-06-01 Smithkline Beecham Biologicals S.A. Vacuna que comprende un conjugado antigeno polisacarido-proteina transportadora y proteina transportadora libre.
GB9513074D0 (en) 1995-06-27 1995-08-30 Cortecs Ltd Novel anigen
US6290970B1 (en) 1995-10-11 2001-09-18 Aventis Pasteur Limited Transferrin receptor protein of Moraxella
US6090576A (en) 1996-03-08 2000-07-18 Connaught Laboratories Limited DNA encoding a transferrin receptor of Moraxella
SE9601158D0 (sv) 1996-03-26 1996-03-26 Stefan Svenson Method of producing immunogenic products and vaccines
US6245335B1 (en) * 1996-05-01 2001-06-12 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
JP2000511411A (ja) 1996-05-01 2000-09-05 ザ ロックフェラー ユニヴァーシティ 抗―肺炎球菌ワクチン用のコリン結合タンパク質
US7341727B1 (en) 1996-05-03 2008-03-11 Emergent Product Development Gaithersburg Inc. M. catarrhalis outer membrane protein-106 polypeptide, methods of eliciting an immune response comprising same
JPH102001A (ja) * 1996-06-15 1998-01-06 Okajima Kogyo Kk グレーチング
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
FR2763244B1 (fr) * 1997-05-14 2003-08-01 Pasteur Merieux Serums Vacc Composition vaccinale multivalente a porteur mixte
CA2292838A1 (en) 1997-06-03 1998-12-10 Connaught Laboratories Limited Lactoferrin receptor genes of moraxella
JP2001510031A (ja) 1997-07-21 2001-07-31 ノース・アメリカン・ヴァクシン・インコーポレーテッド ワクチンとしての修飾された免疫原ニューモリシン組成物
US6224880B1 (en) * 1997-09-24 2001-05-01 Merck & Co., Inc. Immunization against Streptococcus pneumoniae using conjugated and unconjugated pneumoccocal polysaccharide vaccines
GB9727262D0 (en) * 1997-12-24 1998-02-25 Smithkline Beecham Biolog Vaccine
US20050031638A1 (en) * 1997-12-24 2005-02-10 Smithkline Beecham Biologicals S.A. Vaccine
US6709658B1 (en) * 1998-02-12 2004-03-23 Wyeth Holdings Corporation Pneumococcal vaccines formulated with interleukin-12
KR20060126844A (ko) 1998-04-07 2006-12-08 메디뮨 인코포레이티드 백신용 폐렴 구균의 콜린 결합성 단백질의 유도체
GB9812613D0 (en) 1998-06-11 1998-08-12 Smithkline Beecham Biolog Vaccine
WO2000010599A2 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
EP2050464B1 (en) * 1998-12-21 2019-08-07 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
DE60043930D1 (de) 1999-03-19 2010-04-15 Glaxosmithkline Biolog Sa Impfstoff gegen kapsulare polysaccharide von streptococcus pneumoniae
GB9909077D0 (en) * 1999-04-20 1999-06-16 Smithkline Beecham Biolog Novel compositions
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
CN201252175Y (zh) * 2008-08-04 2009-06-03 富士康(昆山)电脑接插件有限公司 线缆连接器组件

Also Published As

Publication number Publication date
NO20014323D0 (no) 2001-09-05
IL145043A0 (en) 2002-06-30
WO2000056358A2 (en) 2000-09-28
HK1043728B (zh) 2007-06-22
US20110217329A1 (en) 2011-09-08
AR022965A1 (es) 2002-09-04
EP1162999A2 (en) 2001-12-19
MXPA01009452A (es) 2002-08-06
US20100119544A1 (en) 2010-05-13
DE60038166T2 (de) 2009-03-12
IL145044A (en) 2007-03-08
PL204890B1 (pl) 2010-02-26
IL145044A0 (en) 2002-06-30
DE122009000054I1 (de) 2009-12-31
AU750762B2 (en) 2002-07-25
EP1880735A2 (en) 2008-01-23
ATE346608T1 (de) 2006-12-15
JP4846906B2 (ja) 2011-12-28
WO2000056359A2 (en) 2000-09-28
NO2011014I2 (no) 2011-08-30
CA2366314A1 (en) 2000-09-28
HU229968B1 (hu) 2015-03-30
AU750913B2 (en) 2002-08-01
PT1162999E (pt) 2007-02-28
KR100642044B1 (ko) 2006-11-10
CN1351501A (zh) 2002-05-29
EP1776962A1 (en) 2007-04-25
DE60038166D1 (de) 2008-04-10
JP2002540074A (ja) 2002-11-26
DK1162999T3 (da) 2007-03-26
CZ301445B6 (cs) 2010-03-03
CA2365296A1 (en) 2000-09-28
NZ513840A (en) 2004-02-27
NO2011014I1 (no) 2011-09-19
PL355264A1 (en) 2004-04-05
JP2011057713A (ja) 2011-03-24
ES2339737T3 (es) 2010-05-25
CZ20013379A3 (cs) 2002-03-13
NL300415I1 (nl) 2009-12-01
PL203917B1 (pl) 2009-11-30
CY2009014I1 (el) 2010-07-28
TWI281403B (en) 2007-05-21
WO2000056358A3 (en) 2001-01-04
NL300415I2 (pt) 2016-12-13
NO20014325D0 (no) 2001-09-05
ATE459373T1 (de) 2010-03-15
EP1163000A2 (en) 2001-12-19
LU91652I9 (pt) 2019-01-03
AR022964A1 (es) 2002-09-04
NO20014325L (no) 2001-11-14
NO20014323L (no) 2001-11-14
CZ303653B6 (cs) 2013-01-30
EP1163000B1 (en) 2008-02-27
JP2002539273A (ja) 2002-11-19
ES2300255T3 (es) 2008-06-16
EP1162998A2 (en) 2001-12-19
CN1192798C (zh) 2005-03-16
TWI286938B (en) 2007-09-21
AU750788B2 (en) 2002-07-25
EP1880735A3 (en) 2008-03-12
US20030147922A1 (en) 2003-08-07
BRPI0009163B1 (pt) 2019-04-09
AU3813600A (en) 2000-10-09
AU3430700A (en) 2000-10-09
WO2000056360A3 (en) 2001-01-25
KR20020000549A (ko) 2002-01-05
CY1107561T1 (el) 2013-03-13
US20050031646A1 (en) 2005-02-10
HU228499B1 (en) 2013-03-28
HK1043730A1 (zh) 2002-09-27
CY1107390T1 (el) 2010-07-28
IL145045A0 (en) 2002-06-30
MY125202A (en) 2006-07-31
BR0009166A (pt) 2001-12-26
TR200102735T2 (tr) 2002-04-22
US20150079125A1 (en) 2015-03-19
DE60043930D1 (de) 2010-04-15
EP1162998B1 (en) 2010-03-03
HK1043731A1 (en) 2002-09-27
KR20020000785A (ko) 2002-01-05
CY2009014I2 (el) 2010-07-28
HUP0200373A2 (en) 2002-06-29
US9168313B2 (en) 2015-10-27
JP2002540075A (ja) 2002-11-26
EP2277535A3 (en) 2011-03-09
BR0009154A (pt) 2001-12-26
FR10C0008I1 (fr) 2010-03-26
ATE387214T1 (de) 2008-03-15
CN1351503A (zh) 2002-05-29
PL355178A1 (en) 2004-04-05
NO330532B1 (no) 2011-05-09
WO2000056359A3 (en) 2001-02-01
DE60032120D1 (de) 2007-01-11
EP2277535A2 (en) 2011-01-26
TR200102736T2 (tr) 2002-04-22
KR100798212B1 (ko) 2008-01-24
HK1043728A1 (en) 2002-09-27
JP5551579B2 (ja) 2014-07-16
EP1162999B1 (en) 2006-11-29
WO2000056360A2 (en) 2000-09-28
MY125387A (en) 2006-07-31
CN1191852C (zh) 2005-03-09
AR022963A1 (es) 2002-09-04
PL355180A1 (en) 2004-04-05
IL145043A (en) 2007-06-17
BE1025464I2 (pt) 2019-03-06
NZ513841A (en) 2001-09-28
NO20014322D0 (no) 2001-09-05
LU91652I2 (fr) 2010-10-13
CA2366152A1 (en) 2000-09-28
CN100339130C (zh) 2007-09-26
CZ20013380A3 (cs) 2002-03-13
ES2275499T3 (es) 2007-06-16
US20060002961A1 (en) 2006-01-05
CA2366314C (en) 2012-01-10
KR20020001785A (ko) 2002-01-09
SI1162999T1 (sl) 2007-04-30
HUP0200367A2 (en) 2002-05-29
US20060093626A1 (en) 2006-05-04
SI1163000T1 (sl) 2008-06-30
NO330736B1 (no) 2011-06-27
US20100291138A1 (en) 2010-11-18
HUP0200664A2 (en) 2002-06-29
US8926985B2 (en) 2015-01-06
TR200102739T2 (tr) 2001-12-21
NZ513842A (en) 2004-05-28
NO20014322L (no) 2001-11-14
FR10C0008I2 (fr) 2012-10-26
CN1391481A (zh) 2003-01-15
HUS1500040I1 (hu) 2018-05-28
AU3291900A (en) 2000-10-09
BRPI0009163B8 (pt) 2021-05-25
TWI235064B (en) 2005-07-01
DE60032120T2 (de) 2007-09-20
HK1043731B (zh) 2009-01-23
DK1163000T3 (da) 2008-04-28
CZ20013378A3 (cs) 2002-03-13
BR0009163A (pt) 2001-12-26

Similar Documents

Publication Publication Date Title
HK1043731A1 (en) Vaccine against antigens from bacteriae
HUS1300072I1 (hu) Vakcina
HUP0200527A2 (en) Use of antibodies for anticancer vaccination
IL189736A0 (en) Vaccine adjuvants
GB9915204D0 (en) Vaccine
GB9901254D0 (en) Vaccines
EP1210364A4 (en) VACCINE ANTIGENS FROM MORAXELLA
GB9906437D0 (en) Vaccine
MXPA01010701A (es) Vacuna.
GB9913327D0 (en) Vaccine
GB9915419D0 (en) Antigens
GB9911823D0 (en) New vaccine formulations
GB9909072D0 (en) Vaccine
GB9929923D0 (en) Antigen preparations
GB9917144D0 (en) Vaccine
GB9905511D0 (en) Vaccine
GB9916677D0 (en) Vaccine
GB9927336D0 (en) Vaccine
GB9925619D0 (en) Vaccine
GB9925618D0 (en) Vaccine
GB9915205D0 (en) Vaccine
GB9922701D0 (en) Vaccine
GB9922700D0 (en) Vaccine
GB9919260D0 (en) Vaccine
GB9918647D0 (en) Vaccine